Creo (stand 1125) is an ingredients technology company that focuses on one of the world's fastest growing ingredient classes— cannabinoids—that it produces using the natural process of fermentation. Creo’s mission is to enable the creation of value-added cannabinoid products that help people everywhere, at scale and in a more environmentally sustainable way using advanced biology instead of the cannabis plant. Creo’s technology partner and major shareholder is industry-leading biotechnology firm Genomatica.

Creo operates legally in the US on both a federal and state level. Its products contain no THC, are not regulated by the DEA, and are not considered “drugs” by the FDA.
 
Recently Creo launched its first products—CBG/CBGA produced through fermentation. A growing body of studies is supporting CBG’s ability to potentially reduce inflammation, sooth and calm redness, combat acne, regulate circadian rhythm and detoxification, support wound healing and help regulate pigmentation.
 
More info: Creo, Tel: 408-780-5687; Email: [email protected]; Website: www.creoingredients.com